ASX Announcement

29 October 2026

Tissue Repair ("TRP") SEPTEMBER 2026 APPENDIX 4C

29 October 2026 - Tissue Repair Limited (ASX:TRP, TRP or the Company) is pleased to update the market on its progress in the Sept 2026 quarter and attaches its Appendix 4C Quarterly Cashflow Report for the period.

Key Highlights and Update

- US Phase III chronic wound trial approximately 112 patients randomised and recruitment continuing.
- Medical Device applications remain a key focus as an alternative pathway to a new drug approval which would not require the full phase III patient recruitment plan. US FDA 510(k) submission targeted for April 2027and European CE Mark class II submission anticipated thereafter.
- Favourable US reimbursement framework established following April 2026 regulatory changes, indicating potential reimbursement of approximately US$1,270 per 10g tube in wound clinic settings.
- TR Pro+ Australian commercial launch progressing, with all three product formats (10g, 30g and 200g professional back bar) now in market. TRP resumed direct distribution of TR Pro+ in the aesthetics channel, alongside existing distribution into the medical channel.
- Manufacturing scale-up costs materially reduced, with a second-hand centrifuge expected to accelerate pilot API production while avoiding significant capital expenditure. The centrifuge has been procured, and commercial terms have been agreed with the contract manufacturer. Manufacturing supply agreement and GMP agreement are currently under review.
- Strong cash position of $4.74 million at quarter end, supplemented by receipt of a $1.9 million R&D Tax for FY25 Incentive refund on 1 July 2026.

Operational Update

TR-987 – Chronic Wounds

The Company's US Phase III clinical trial continues to progress well, with approximately 112 patients now randomised. Patient recruitment remains ongoing.

TRP continues to progress its regulatory objectives in the US and Europe. The Company is actively evaluating medical device approval as an alternative to a new drug approval as a lower cost, faster path to market. Importantly, recent regulatory reimbursement changes in April 2026 have significantly strengthened the commercial opportunity for a device pathway. The company now expects to submit its US FDA (510k) application in April 2027 following the completion of final verification and validation studies (V&V), with all supporting non-clinical testing reports related to chemical characterisation, biological evaluation and packaging integrity, expected in Q1 2027. This revised timeline reflects the comprehensive data package being assembled to support the regulatory submission.

+ See chapter 19 of the ASX Listing Rules for defined terms.

TR Pro+ – Global Acute and Aesthetic Wound Opportunity

Following regulatory approval as a medical device, TRP intends to pursue the substantially larger global acute wound market.

In preparation for an expanded product, channel and geographic strategy, work is progressing on brand architecture, brand identity, packaging and brand guidelines.

In Australia, all product sizes (10g, 30g and 200g) from the first commercial GMP production run of TR Pro+ as a TGA-listed medicine, were released and are available in market. Finished product process validation has been successfully completed, with three validation batches manufactured in accordance with TGA requirements to support commercial launch in Australia.

TRP resumed direct distribution of TR Pro+ in the aesthetic channel. Initial sales results are promising as our sales team connects with prior and new aesthetic clinic relationships. As the Company is developing a new category of wound care products focussed on **active repair** of skin and wounds, including post aesthetic and minor surgical procedures, it is beneficial to have a close, direct relationship with our clinic partners. Hence the desire, to resume direct distribution in the Australian market.

Strategic Milestones

Initiative	Current Status	Target Timing
FDA 510(k) & CE Mark	Verification, validation activities and dossier preparation progressing. Submission targeted for April 2027.	Submission April 2027. Estimated approval within 6–12 months.
Phase III Clinical Trial	Approximately 112 patients randomised. Recruitment continuing.	Ongoing.
CMC Manufacturing Scale-up	Scale-up manufacturing partner secured. Low-cost centrifuge solution expected to materially reduce capital expenditure while accelerating pilot production. Centrifuge ordered and supplier performing shipment readiness activities.	Supplier timeline to be confirmed following replacement and installation of new components ahead of shipment.
Australian Commercialisation	Brand strategy and identity program continuing with external branding agency.	Ongoing.
Medical Advisory Board	Eight Key Opinion Leaders (KOLs) have joined the Medical Advisory Board in addition to the Chair, Dr Steven Liew. The KOLs collective expertise span aesthetic treatments, dermatology, skin cancer treatment, chronic and difficult to heal wound care, orthopaedic surgery and wound research.	First meeting is scheduled for early November 2026.

Corporate and Financial Summary

The Company's cash position as at 30 September 2026 was $4.740 million. During the September 2026 quarter, the Company recorded net operating cash outflows of $19k, after receipt on 1 July 2026 of the FY25 R&D Tax Incentive refund of $1.940 million foreshadowed in the June 2026 quarterly report. Excluding this receipt, underlying net operating cash outflows were $1.959 million, broadly in line with the June 2026 quarter ($1.848 million) and reflecting continued investment in the US Phase III clinical trial, TR-987 development and the Australian commercial launch of TR Pro+.

Operating cash outflows were primarily attributable to research and development expenditure of $1.055 million (June 2026 quarter: $1.09 million), of which approximately $978k related to the Phase III clinical trial program, product manufacturing and operating costs of $320k (including final payments for beta glucan API spray drying and GMP release testing, and packaging and freight for the first commercial production run of TR Pro+), staff costs of $312k, advertising and marketing of $83k and administration and corporate costs of $360k. Administration and corporate costs were higher than the June 2026 quarter ($249k), reflecting annual ASX listing fees, insurance premiums and audit fees paid during the quarter, legal and advisory costs associated with the proposed delisting and share buy-back, and the timing of Executive Director fee payments. These outflows were partially offset by customer receipts of $153k and interest income of $18k, with the lower interest receipt reflecting the timing of interest payments on the Company's term deposits.

The Company continues to actively manage its cash position while progressing its development and commercialisation activities. Following shareholder approval on 18 September 2026 of the Company's removal from the official list of ASX and of an off-market equal access share buy-back of up to $1.0 million at $0.13 per share, the buy-back offer opened on 29 September 2026 and closes on 27 October 2026, with payment to participating shareholders expected on or about 30 October 2026. The buy-back will be funded from existing cash reserves and is not reflected in the September 2026 quarter cash flows. The Company also expects to receive its FY26 R&D Tax Incentive refund, estimated at $2.2 million, following lodgement of its FY26 income tax return.

A summary of operating cash flows for the period ended 30 September 2026, compared with the intended use of funds outlined in the Company's Prospectus dated 7 October 2021, is provided below:

	Use of Funds under Prospectus	**Actual use of funds for the period ending 30 September 2026**
Working capital and overheads[1]	300,000[1]	7,229,000[1]
Offer costs	2,300,000	1,849,000
Development of Chronic Wound Drug	3,700,000	12,583,000
Phase III Clinical Trials	13,600,000	6,549,000
Commercialisation of Aesthetic Product	2,100,000	4,806,000
Interest received	-	(1,737,000)
R&D tax incentive refund	-	(4,801,000)
TR Pro+ ™ Sales receipts	-	(1,299,000)
Total	**22,000,000**	**25,179,000**

[1]The Company raised $7.5million via a convertible note in April 2021 (pre-IPO) which has been allocated to fund a significant portion of the working capital and overheads of the Company. The working capital and overhead cash outflows are broadly in line with the forecast budget. The Company believes the working capital outflows are consistent with the requirements for an ASX listed biotech Company of its size.

In accordance with Listing Rule 4.7C, payments made to related parties and their associates included in item 6.1 of the Appendix 4C were $136,000. This includes payments for remuneration of director fees to executive and non-executive directors in the normal course of business at commercial rates including superannuation, and consulting fees paid to a non-executive director for services outside Board duties at commercial rates, excluding reimbursements of out-of-pocket expenses. The increase from the June 2026 quarter ($73,000) primarily reflects the timing of Executive Director fee payments, with four monthly payments falling within the quarter.

This announcement has been approved for release by TRP's board

--ENDS-

About Tissue Repair

Tissue Repair Limited (ASX:TRP) is a Phase 3 advanced biotechnology company developing second generation wound healing agents. The Company's core focus is entering Phase 3 clinical trials in chronic wounds for its lead drug candidate TR987®, with a secondary focus on commercialising TR Pro+® a post procedure topical gel to accelerate healing and improve skin quality following cosmetic and medical procedures, as well as other acute wound products in its pipeline. The Company's longer-term strategy is to commercialise its propriety Glucoprime® API to treat a variety of wounds and skin conditions.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
Tissue Repair Limited	
ABN	**Quarter ended ("current quarter")**
20 158 411 566	30 September 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (3 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	153	153
1.2	Payments for		
	(a) research and development	(1,055)	(1,055)
	(b) product manufacturing and operating costs	(320)	(320)
	(c) advertising and marketing	(83)	(83)
	(d) leased assets	-	-
	(e) staff costs	(312)	(312)
	(f) administration and corporate costs	(360)	(360)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	18	18
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	1,940	1,940
1.8	Other (provide details if material)		
1.9	**Net cash from / (used in) operating activities**	**(19)**	**(19)**

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**-**	**-**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	**Net cash from / (used in) financing activities**	**-**	**-**

Consolidated statement of cash flows	Current quarter $A'000	Year to date (3 months) $A'000

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	4,759	4,759
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(19)	(19)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	-
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	**Cash and cash equivalents at end of period**	**4,740**	**4,740**

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	**Current quarter $A'000**	**Previous quarter $A'000**
5.1	Bank balances	1,639	1,676
5.2	Call deposits	3,101	3,083
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**4,740**	**4,759**

6.	**Payments to related parties of the entity and their associates**	**Current quarter $A'000**
6.1	Aggregate amount of payments to related parties and their associates included in item 1	136
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

The amount at 6.1 includes Director fees (including superannuation) for Non-Executive Directors, Executive Director fees paid to an entity associated with the Executive Director, and consulting fees paid to a Non-Executive Director for services outside Board duties.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	**-**	**-**

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(19)
8.2	Cash and cash equivalents at quarter end (item 4.6)	4,740
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	4,740
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	**249**

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

Item 8.1 includes the receipt of the R&D Tax Incentive refund of $1,940k on 1 July 2026. Excluding this receipt, net cash used in operating activities for the quarter was $1,959k, which equates to approximately 2.4 quarters of funding available at 30 September 2026. The off-market equal access share buy-back of up to $1.0 million approved by shareholders on 18 September 2026 is funded from existing cash reserves and completes on 29 October 2026, after quarter end; on a pro forma basis after a $1.0 million buy-back, available funding would be approximately $3,740k, or approximately 1.9 quarters on the same underlying basis.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

29 October 2026

Date: .....

The Board

Authorised by: .....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.